Overview

• Assembly Biosciences Q3 net loss narrows to $9.2 mln, EPS at -$0.72

• Company raised $175 mln from equity financing to support clinical developments

• Positive Phase 1b results for ABI-5366 show reduced viral shedding in genital herpes

Outlook

• Company expects interim Phase 1b HSV data by year-end

• Company plans to initiate Phase 2 study of ABI-5366 in mid-2026

• Assembly Bio's cash position projected to fund operations into late 2027

Result Drivers

• REVENUE - Revenue from collaborative research with Gilead rose to $10.8 mln from $6.8 mln, reflecting increased research and development incurred under the collaboration as well as an increase in collaboration funding

• R&D EXPENSES - Costs rose due to increase in spending on the company's HSV program

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Assembly Biosciences Inc is $38.00, about 17.9% above its November 7 closing price of $31.20

Press Release: ID:nGNX8lDbfM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)